Vasomune Therapeutics
PrivateLast Round
Strategic
Nov 25, 2025
Total Funding Raised
$14.75M
Company Overview
Vasomune Therapeutics operates in Healthcare & Life Sciences and is based in Toronto. Its latest recorded funding round was a Series A round in January 2023.
Vasomune Therapeutics is a biotechnology company that develops novel therapeutics for diseases associated with vascular dysfunction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vasomune Therapeutics Comparables
Compare Vasomune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AnGes, Inc. | 83% | |
| Adrenomed AG | 78% | |
| Aqualung Therapeutics Corporation | 77% |
For institutional investors. Book with your work email.
Vasomune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Nov 25, 2025 | ||||
| Series A | Jan 1, 2023 | ||||
| Grant | Nov 8, 2021 | ||||
| Grant | Nov 8, 2021 | ||||
| Grant | Aug 18, 2020 | ||||
Seed | Oct 20, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vasomune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of War | Grant |
| National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) | Grant |
| Genome Canada | Seed |
| TIAP | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 10, 2025
Presented at the OBIO(R) Investment Summit.
- Apr 7, 2024
Grew 50% QoQ from 6 to 9 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 6, 2026
Vasomune presents at the OBIO(R) Investment Summit.
- is_developingSep 28, 2026
Vasomune develops Pegevongitide (AV-001) under a co-development agreement with AnGes, Inc., and completes enrollment in its randomized, double-blind, placebo-controlled Phase 2a study of hospitalized pneumonia patients requiring supplemental oxygen in Canada on Sep 28th '26.
For institutional investors. Book with your work email.
Vasomune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vasomune Therapeutics's valuation, stock price, and market status.
Is Vasomune Therapeutics a public or private company?
Vasomune Therapeutics is a private company.
What is the current stock price of Vasomune Therapeutics?
Vasomune Therapeutics is a private company, so its shares have no public market price. Caplight tracks Vasomune Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vasomune Therapeutics worth (valuation)?
Valuation information for Vasomune Therapeutics is not publicly available.
Can I buy Vasomune Therapeutics stock?
Vasomune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vasomune Therapeutics's last funding round?
Vasomune Therapeutics's most recent funding round was Strategic on November 25, 2025.
Who are the main investors in Vasomune Therapeutics?
Key investors in Vasomune Therapeutics include U.S. Department of War, National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), Genome Canada, TIAP.
Will Vasomune Therapeutics IPO soon?
No public IPO plans have been announced for Vasomune Therapeutics.
How can I track Vasomune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Vasomune Therapeutics's shares on secondary markets.